Oriflame granted EU patent for novel anti-ageing active following ‘groundbreaking’ research

Oriflame has achieved an important milestone in its strategic focus on skin care, after the Swedish firm was granted an EU patent for its novel active ingredient, Aspartolift, which has clinically proven anti-ageing skin benefits. 

The patent (EP2729220) was granted by the European Patent Organization relating to the discovery of the novel active ingredient, acetyl aspartic acid, Aspartolift. 

According to Oriflame, it is the key active ingredient in the Ultimate Lift range which is a part of the new flagship brand, NovAge.

‘Groundbreaking’ research

The discovery of the natural amino acid derivative as a potential active ingredient to treat ageing skin was made after Oriflame’s research team undertook vast research, much of which was published in a supplement in the International Journal of Cosmetic Science.

This saw many studies done on the efficacy and safety of the ingredient, in line with EU requirements, and the team say its potential is based on its mimicking gene activity of retinoic acid as a drug, which is also known for its beneficial effect on photo-damaged skin and skin firmness.

”Considering consumer expectations and demand, we were prompted to target our research on the discovery of novel active ingredients focusing on maintaining skin firmness.” says Dr Alain Mavon, Senior Director of the Oriflame Skin Research Institute in Stockholm, Sweden. 

As a result, a new skin care range has been developed which delivers clinically proven anti-ageing benefits.”

Skin care focus

Oriflame says it is focusing its research projects aiming to meet a greater demand for skin care products supported by scientific rationale, active ingredients, and clinical proof of efficacy.

”This type of groundbreaking research will enable Oriflame to be at the forefront of advanced, scientific-based technology, further strengthening our heritage category Skin Care,” adds Magnus Brannström, Oriflame President and CEO.